US Biotechnology Market to Hit $1.14 Trillion by 2035 as AI and Gene Therapies Drive 13.7% CAGR
Updated
Updated · Precedence Research · Jun 9
US Biotechnology Market to Hit $1.14 Trillion by 2035 as AI and Gene Therapies Drive 13.7% CAGR
3 articles · Updated · Precedence Research · Jun 9
Summary
$1.14 trillion is the projected size of the U.S. biotechnology market by 2035, up from $316.41 billion in 2025 and $361.07 billion in 2026.
13.7% annual growth is being driven by rising chronic and rare diseases, which are lifting demand for precision biologics, gene therapies and other personalized treatments.
AI is accelerating that expansion by speeding drug discovery, clinical-trial design and manufacturing workflows, while bio-pharmacy led the market in 2025 and bio-informatics is forecast to grow fastest.
Tissue engineering and regeneration held the largest technology share in 2025, while chromatography is expected to post the strongest growth as biotherapeutic purification and quality-control needs rise.
The outlook is supported by FDA approvals, orphan-drug incentives and onshoring investment, though regulatory complexity, manufacturing bottlenecks and tighter venture funding still threaten scalability.
Beyond the AI boom, which overlooked technology will spark the next revolution in biotechnology and medicine?
As AI slashes drug discovery costs, will patients see lower prices or just higher industry profits?
With AI designing future drugs, how can society prevent algorithmic bias from creating new health inequities?
Transforming US Biotech: AI, Gene Therapy, and Market Dynamics Through 2035
Overview
The US biotechnology market is experiencing rapid growth, driven by a surge in FDA approvals and strategic changes in therapeutic development. In 2025, biopharma companies introduced 55 new drugs and biologics, while the cell and gene therapy sector saw a notable increase in approvals and new indications. The FDA is not only accelerating approvals but also emphasizing strong safety standards and early planning for manufacturing and controls. These developments highlight a dynamic and innovative landscape, where regulatory support and industry adaptation are enabling faster access to advanced therapies and shaping the future of healthcare.